Synovial Fibroblast 3.1: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 1 of 2) - Dataset (ID:20234)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA2159 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | IFN-g | 55.0 | 46 | |
RA2159 | Poly(I:C) | 2 | ug/mL | 4 | IFN-g | 58.0 | 29 | ||||
N2645 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | IFN-g | 26.0 | 23 | |
N2645 | Poly(I:C) | 2 | ug/mL | 4 | IFN-g | 31.0 | 32 | ||||
RA2708 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | IFN-g | 82.0 | 33 | |
RA2708 | Poly(I:C) | 2 | ug/mL | 4 | IFN-g | 67.0 | 24 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | IFN-g | 19.0 | 53 | |
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | IFN-g | 30.0 | 45 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | IFN-g | 18.0 | 40 | |
N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | IFN-g | 25.0 | 51 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | IFN-g | 16.0 | 34 | |
RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | IFN-g | 44.0 | 38 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | IFN-g | 85.0 | 51 | |
RA2159 | IL-1 alpha | 100 | ng/mL | 4 | IFN-g | 90.0 | 29 | ||||
N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | IFN-g | 47.5 | 32 | |
N2645 | IL-1 alpha | 100 | ng/mL | 4 | IFN-g | 58.0 | 37 | ||||
RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | IFN-g | 88.0 | 19 | |
RA2708 | IL-1 alpha | 100 | ng/mL | 4 | IFN-g | 91.0 | 34 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | IFN-g | 105.0 | 51 | |
RA2159 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | IFN-g | 106.0 | 43 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | IFN-g | 40.5 | 38 | |
N2645 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | IFN-g | 90.0 | 36 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | IFN-g | 94.0 | 46 | |
RA2708 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | IFN-g | 82.0 | 43 | |
RA2159 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | IFN-g | 101.0 | 53 |